The results of the MONARCH 3 trial, presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract 236O_PR), showed that adding the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to endocrine therapy improved progression-free survival compared to endocrine therapy alone in the total study population. While most women had substantial benefit from the addition of abemaciclib as initial treatment, around one-third of women may not need a CDK 4/6 inhibitor as initial treatment.
MONARCH 3 was a phase III randomized, double-blind trial of abemaciclib vs placebo, both in addition to endocrine therapy with a nonsteroidal aromatase inhibitor (anastrozole or letrozole), as initial therapy in postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer. The study included 493 patients from 22 countries who had never been treated for metastatic disease. The primary endpoint was progression-free survival.
Results of the interim analysis at 18 months were presented at ESMO.
The investigators found that compared to single agent endocrine therapy alone, the combination of abemaciclib and endocrine therapy significantly prolonged progression-free survival, with a hazard ratio (HR) of 0.543 (P = .000021). In patients with measurable disease, the objective response rate was 59% in the abemaciclib arm and 44% in the placebo arm (P = .004). Rates of diarrhea and neutropenia were 81.3% and 41.3% with abemaciclib, and 29.8% and 1.9% with placebo, respectively.
“This is the third study demonstrating that the combination of endocrine therapy with a CDK4/6 inhibitor is better than endocrine therapy alone,” said lead author Angelo Di Leo, MD, PhD, medical oncologist, Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy. “Abemaciclib reduced the risk of disease progression by 46%.”
The data also show that investigators may be able to better distinguish benefit among groups of patients. In patients with more challenging disease characteristics such as liver metastases, patients had substantial benefit from the addition of abemaciclib. However, in subgroups with bone metastases only, or with indolent disease relapsing years after stopping adjuvant endocrine therapy, patients had an excellent prognosis with endocrine therapy alone.
“It is well known that these patients have a better prognosis than those with liver or lung metastases or [those] who relapse early during the course of adjuvant endocrine therapy,” said Dr. Di Leo. “Now for the first time, we have insights suggesting that patients with certain clinical characteristics may benefit differently from treatment with a CDK 4/6 inhibitor, including the possibility that some patients with a good prognosis may be able to start on endocrine therapy alone. In such patients, CDK 4/6 inhibitors could potentially be reserved as a next line of treatment for metastatic disease. This idea warrants further study given our data.”
“In our study, nearly one-third of patients had bone metastases only or a tumor relapsing several years after stopping adjuvant endocrine therapy,” continued Dr. Di Leo. “This is a clinically relevant proportion of patients for whom we may consider delaying use of a CDK 4/6 inhibitor. This may be a more optimal treatment strategy for some patients, since it can avoid the toxicity of first line CDK 4/6 inhibitors and save costs.”
Commenting on the findings, Giuseppe Curigliano, MD, PhD, Director, Division of New Drug Development, European Institute of Oncology (IEO), University of Milan, Milan, Italy, said, “Abemaciclib is the third CDK4/6 inhibitor to be tested in advanced breast cancer, and the MONARCH 3 trial confirms the role of this new class of agents in combination with endocrine therapy in the treatment of metastatic breast cancer.”
“Many patients with metastatic disease still receive chemotherapy, despite guidelines and data from clinical trials,” he added. “This study confirms that we should avoid chemotherapy in hormone receptor–positive, HER2-negative metastatic breast cancer if visceral crisis is not present.”
Dr. Curigliano concluded, “The major question that still needs to be answered is the optimal sequence of treatment in the era of CDK 4/6 inhibitors. Should we use these agents in the first line setting, or is there a space to start with endocrine therapy alone and to add CDK 4/6 inhibitors at progression? An academic-driven trial should be designed to address this question.”
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.